![Yu Chen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yu Chen
Direktor/Vorstandsmitglied bei Genor Biopharma Co., Ltd.
Aktive Positionen von Yu Chen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Genor Biopharma Co., Ltd.
![]() Genor Biopharma Co., Ltd. BiotechnologyHealth Technology Genor Biopharma Co., Ltd. engages in the manufacture and development of antibodies and related biological products. Its business scope includes research and development of monoclonal antibodies and biological products; research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products; and wholesale, import and export of instruments, mechanical equipment, pharmaceutical equipment, and pharmaceutical intermediates. The company was founded on December 4, 2007 and is headquartered in Shanghai, China. | Direktor/Vorstandsmitglied | - | - |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
![]() PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Direktor/Vorstandsmitglied | 01.07.2021 | - |
Karriereverlauf von Yu Chen
Ehemalige bekannte Positionen von Yu Chen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ZHAOKE OPHTHALMOLOGY LIMITED | Direktor/Vorstandsmitglied | 23.10.2020 | 08.04.2024 |
GENOR BIOPHARMA HOLDINGS LIMITED | Direktor/Vorstandsmitglied | 03.12.2018 | 02.01.2024 |
GEMPHARMATECH CO., LTD. | Direktor/Vorstandsmitglied | 01.08.2020 | 04.04.2023 |
SUZHOU NANOMICRO TECHNOLOGY CO., LTD. | Direktor/Vorstandsmitglied | 01.02.2020 | 30.03.2022 |
Shanghai Panxin Equity Investment Management Co. Ltd. | Chief Investment Officer | 01.01.2012 | 01.07.2015 |
Citigroup Global Markets Asia Ltd.
![]() Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Corporate Officer/Principal | 01.09.2010 | 01.06.2011 |
Ausbildung von Yu Chen
Stanford University | Graduate Degree |
Yale University | Graduate Degree |
The Hong Kong University of Science & Technology | Undergraduate Degree |
Statistik
International
China | 6 |
Hong Kong | 4 |
Vereinigte Staaten | 3 |
Operativ
Director/Board Member | 6 |
Graduate Degree | 2 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 4 |
Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
SUZHOU NANOMICRO TECHNOLOGY CO., LTD. | Commercial Services |
GEMPHARMATECH CO., LTD. | Health Technology |
ZHAOKE OPHTHALMOLOGY LIMITED | Health Technology |
GENOR BIOPHARMA HOLDINGS LIMITED | Health Technology |
Private Unternehmen | 4 |
---|---|
Citigroup Global Markets Asia Ltd.
![]() Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Finance |
Genor Biopharma Co., Ltd.
![]() Genor Biopharma Co., Ltd. BiotechnologyHealth Technology Genor Biopharma Co., Ltd. engages in the manufacture and development of antibodies and related biological products. Its business scope includes research and development of monoclonal antibodies and biological products; research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products; and wholesale, import and export of instruments, mechanical equipment, pharmaceutical equipment, and pharmaceutical intermediates. The company was founded on December 4, 2007 and is headquartered in Shanghai, China. | Health Technology |
Shanghai Panxin Equity Investment Management Co. Ltd. | |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
![]() PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Commercial Services |